Effects of HbA1c and weight reduction on blood pressure in patients with type 2 diabetes mellitus treated with exenatide*.

Paul S, Best J, Klein K, Han J, Maggs D

Diabetes, obesity & metabolism16 May 2012Cited by 12 (Europe PMC)

PMID22510305DOI10.1111/j.1463-1326.2012.01609.xPepBankPUB-22510305

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Exenatide (exendin-4).

01HumanNot a test of Exenatide (exendin-4) aloneObservational studyOther
In exenatide-treated diabetes, combined glycaemic and weight response was linked to greater systolic pressure target attainment than reference.
In plain wordsIn patients receiving exenatide, combined glucose and weight improvement was linked to better systolic pressure target attainment than reference.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseSystolic pressure target with dual response
Study
n = 686
Comparator
Reference group failing to reduce both HbA1c and weight below weighted means
Outcome group
Blood pressure · Cardiovascular
Measurements
Higher likelihood
88%
AW versus reference
Source sentences
Summary
Compared with R, patients in AW, A and W groups had a significantly higher likelihood of improving SBP <130 mmHg by 88, 30 and 61%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Using weighted means (WMs) of the longitudinal measures of HbA(1c) and weight, patients were subdivided into four groups at each visit by glycaemic and weight responses; patients who failed to reduce both HbA(1c) and weight below WMs became the reference group (R).
Summary · context
The other three groups corresponded to patients with HbA(1c) reduction (A), weight reduction (W) and both HbA(1c) and weight reduction (AW).
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2251030501
02HumanNot a test of Exenatide (exendin-4) aloneObservational studyOther
In exenatide-treated diabetes, glycaemic response was linked to greater systolic pressure target attainment than reference.
In plain wordsIn patients receiving exenatide, glucose improvement was linked to better systolic pressure target attainment than reference.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseSystolic pressure target with glycaemic response
Study
n = 686
Comparator
Reference group failing to reduce both HbA1c and weight below weighted means
Outcome group
Blood pressure · Cardiovascular
Measurements
Higher likelihood
30%
A versus reference
Source sentences
Summary
Compared with R, patients in AW, A and W groups had a significantly higher likelihood of improving SBP <130 mmHg by 88, 30 and 61%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Using weighted means (WMs) of the longitudinal measures of HbA(1c) and weight, patients were subdivided into four groups at each visit by glycaemic and weight responses; patients who failed to reduce both HbA(1c) and weight below WMs became the reference group (R).
Summary · context
The other three groups corresponded to patients with HbA(1c) reduction (A), weight reduction (W) and both HbA(1c) and weight reduction (AW).
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2251030502
03HumanNot a test of Exenatide (exendin-4) aloneObservational studyOther
In exenatide-treated diabetes, weight response was linked to greater systolic pressure target attainment than reference.
In plain wordsIn patients receiving exenatide, weight improvement was linked to better systolic pressure target attainment than reference.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseSystolic pressure target with weight response
Study
n = 686
Comparator
Reference group failing to reduce both HbA1c and weight below weighted means
Outcome group
Blood pressure · Cardiovascular
Measurements
Higher likelihood
61%
W versus reference
Source sentences
Summary
Compared with R, patients in AW, A and W groups had a significantly higher likelihood of improving SBP <130 mmHg by 88, 30 and 61%, respectively.
2 context sentences(design, population, supporting numbers)
Summary · context
Using weighted means (WMs) of the longitudinal measures of HbA(1c) and weight, patients were subdivided into four groups at each visit by glycaemic and weight responses; patients who failed to reduce both HbA(1c) and weight below WMs became the reference group (R).
Summary · context
The other three groups corresponded to patients with HbA(1c) reduction (A), weight reduction (W) and both HbA(1c) and weight reduction (AW).
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2251030503
04HumanNot a test of Exenatide (exendin-4) aloneObservational studyOther
In exenatide-treated diabetes, combined glycaemic and weight response was linked to greater diastolic pressure target attainment than reference.
In plain wordsIn patients receiving exenatide, combined glucose and weight improvement was linked to better diastolic pressure target attainment than reference.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseDiastolic pressure target with dual response
Study
n = 686
Comparator
Reference group failing to reduce both HbA1c and weight below weighted means
Outcome group
Blood pressure · Cardiovascular
Measurements
Higher likelihood
63%
AW versus reference
Source sentences
Summary
Compared with R, patients in AW, A and W had 63, 13 and 45% higher likelihood of improving DBP <80 mmHg.
2 context sentences(design, population, supporting numbers)
Summary · context
Using weighted means (WMs) of the longitudinal measures of HbA(1c) and weight, patients were subdivided into four groups at each visit by glycaemic and weight responses; patients who failed to reduce both HbA(1c) and weight below WMs became the reference group (R).
Summary · context
The other three groups corresponded to patients with HbA(1c) reduction (A), weight reduction (W) and both HbA(1c) and weight reduction (AW).
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2251030504
05HumanNot a test of Exenatide (exendin-4) aloneObservational studyOther
In exenatide-treated diabetes, glycaemic response was linked to greater diastolic pressure target attainment than reference.
In plain wordsIn patients receiving exenatide, glucose improvement was linked to better diastolic pressure target attainment than reference.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseDiastolic pressure target with glycaemic response
Study
n = 686
Comparator
Reference group failing to reduce both HbA1c and weight below weighted means
Outcome group
Blood pressure · Cardiovascular
Measurements
Higher likelihood
13%
A versus reference
Source sentences
Summary
Compared with R, patients in AW, A and W had 63, 13 and 45% higher likelihood of improving DBP <80 mmHg.
2 context sentences(design, population, supporting numbers)
Summary · context
Using weighted means (WMs) of the longitudinal measures of HbA(1c) and weight, patients were subdivided into four groups at each visit by glycaemic and weight responses; patients who failed to reduce both HbA(1c) and weight below WMs became the reference group (R).
Summary · context
The other three groups corresponded to patients with HbA(1c) reduction (A), weight reduction (W) and both HbA(1c) and weight reduction (AW).
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2251030505
06HumanNot a test of Exenatide (exendin-4) aloneObservational studyOther
In exenatide-treated diabetes, weight response was linked to greater diastolic pressure target attainment than reference.
In plain wordsIn patients receiving exenatide, weight improvement was linked to better diastolic pressure target attainment than reference.
Peptide
Exenatide (exendin-4)
Outcome
IncreaseDiastolic pressure target with weight response
Study
n = 686
Comparator
Reference group failing to reduce both HbA1c and weight below weighted means
Outcome group
Blood pressure · Cardiovascular
Measurements
Higher likelihood
45%
W versus reference
Source sentences
Summary
Compared with R, patients in AW, A and W had 63, 13 and 45% higher likelihood of improving DBP <80 mmHg.
2 context sentences(design, population, supporting numbers)
Summary · context
Using weighted means (WMs) of the longitudinal measures of HbA(1c) and weight, patients were subdivided into four groups at each visit by glycaemic and weight responses; patients who failed to reduce both HbA(1c) and weight below WMs became the reference group (R).
Summary · context
The other three groups corresponded to patients with HbA(1c) reduction (A), weight reduction (W) and both HbA(1c) and weight reduction (AW).
In this study, Exenatide (exendin-4) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Exenatide (exendin-4).
Report a problemFND-2251030506

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.